HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clevudine for hepatitis B.

Abstract
Clevudine is distinguished from other oral agents by its sustained suppression of HBV DNA for several months after cessation of therapy, according to a comprehensive review of hepatitis B in the 2 October 2008 issue of the New England Journal of Medicine. Clevudine is differentiated by i) an unusual activation pathway to the biochemically active triphosphate; ii) a mechanism of action of clevudine triphosphate that inhibits multiple steps of the hepatitis B virus (HBV) intracellular life cycle; iii) a long half-life and iv) significant reduction of covalently closed circular DNA (cccDNA) in animal models. Clevudine was approved and is marketed in South Korea based on two 24-week phase III trials vs. placebo. In these studies with treatment-naïve patients, 59% of 248 HBeAg-positive patients had undetectable HBV DNA after 24 weeks of treatment compared with 92% of 89 HBeAg-negative patients, while the percentage of patients with normal liver enzymes was 68% in the HBeAg-positive patients and 75% in the HBeAg-negative patients (all statistically significant versus placebo). Follow-up studies include trials vs. lamivudine as well as a phase IV study of long-term clevudine. Larger and longer phase III trials in the United States, European Union, Asia and South America of clevudine vs. adefovir are ongoing. An ANRS-sponsored trial of clevudine vs. tenofovir vs. the combination of the two agents is poised to begin. Literature published through November 2008 and presentations from the 59th annual meeting of the American Association for the Study of Liver Diseases held 31 October to 4 November 2008 are included.
AuthorsDavid Leif Anderson
JournalDrugs of today (Barcelona, Spain : 1998) (Drugs Today (Barc)) Vol. 45 Issue 5 Pg. 331-50 (May 2009) ISSN: 1699-3993 [Print] Spain
PMID19584963 (Publication Type: Journal Article, Review)
CopyrightCopyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved.
Chemical References
  • Antiviral Agents
  • Arabinofuranosyluracil
  • clevudine
Topics
  • Animals
  • Antiviral Agents (administration & dosage, pharmacology, therapeutic use)
  • Arabinofuranosyluracil (administration & dosage, analogs & derivatives, pharmacology, therapeutic use)
  • Hepatitis B, Chronic (drug therapy)
  • Humans

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: